Clinical Research Committee
The Clinical Research Committee promotes clinical and translational research through resource sharing among CAHON members.
Tian Zhang, MD, MHS (Chair)
Dr. Zhang received her MD from the Harvard-MIT Health Sciences and Technology (HST) program and completed post-graduate training at Duke University, where she remained on faculty until 2021. She is currently Associate Professor, Associate Director of Clinical Research in the Simmons Comprehensive Cancer Center, as well as Director of Clinical Research within the Division of Hematology and Oncology and Department of Internal Medicine at University of Texas Southwestern Medical Center. Clinically she specializes in genitourinary malignancies and is a clinical researcher focused on improving novel therapies and biomarkers for patients with renal, prostate, and urothelial cancers. She is the overall study chair for the phase 3 PDIGREE trial for metastatic renal cell carcinoma in the Alliance cooperative group. She co-leads the Women in RCC program in the Kidney Cancer Association and serves as co-chair of the NCI GU Steering Committee Renal Task Force.
Bo Wang, MD (Co-Chair)
Dr. Wang is a board-certified medical oncologist in Eugene, Oregon. He treats patients with a diverse range of cancers with a primary focus on lung and thoracic cancers. He has been principal investigator on over 15 lung cancer clinical studies. He is passionate about increasing patient access to cutting edge clinical trials in the community setting and to this end serves as an executive member of the Sarah Cannon Research Institute Lung Cancer Research Committee.
Dr. Wang grew up on the east coast and received his undergraduate education at Bowdoin College in Maine. Thereafter he went to Albert Einstein College of Medicine for his MD followed by Tufts Medical Center for internal medicine residency, and finally Icahn Mount Sinai School of Medicine in Manhattan for his hematology and oncology fellowship. In his free time, he enjoys fishing, volleyball, basketball, guitar, and spending time with his family.
Ronan Hsieh, MD, MS
Ronan Hsieh, MD is an Assistant Professor in the Division of Hematology and Oncology at the University of Washington. Dr. Hsieh leads many clinical and translational studies in the field of gastrointestinal oncology. He focuses his research on drug development using novel trial design and cancer models such as tissue slice culture and organoids, which he collaborates with translational scientists at Fred Hutch.
Fun facts – Dr. Hsieh grew up in Taiwan, so you can hear him promoting bubble tea as the best beverage in the world all the time. He enjoys hiking and cycling, and naturally he loves Seattle as his new hometown in the U.S.
Jingsong Zhang, MD, PhD
Dr. Zhang is a Genitourinary Oncologist and Interim Vice Chair, Department of Genitourinary Oncology at Moffitt Cancer Center, as well as a Professor of Oncology and Internal Medicine at the University of South Florida College of Medicine. His primary research interest is in integrating tumor evolution dynamics into the treatment for advanced prostate cancer. As the clinical research director of Moffitt cancer center’s genitourinary oncology program, he has been the principal Investigator (PI) and co-investigator of > 50 phase I, II and III clinical studies since joining Moffitt in July 2010. He is also the co-investigator on R21, R01, U01, U54 grants to study adaptive androgen deprivation therapy and immunotherapy in metastatic prostate cancer.
Dr. Zhan is actively engaged in patient care, research, and education, contributing significantly to the advancement of hematology and oncology both through her clinical practice and academic endeavors.
Feng-ming (Spring) Kong, MD, PhD
Dr. Kong is an American Board-Certified Radiation Oncologist. She is the leader of a Shenzhen Peacock Project on Innovative Clinical Trial Platform & RT and Immunotherapy while also works as Professor and Director of Imaging and Blood Biomarker Group (IBBG) at the University of Hong Kong. She is the Director of Thoracic Oncology and Deputy Director of Medical Cancer Center at Hong Kong University Shenzhen Hospital. Dr. Kong has served as the President of Global Collaborative Oncology Group (GCOG) since 2019. She is a Fellow of American College of Radiology (FACR), Fellow of American Association for Women Radiologists/Radiation Oncologists (FAAWR), and Fellow of American Society of Radiation Oncology (FASTRO). She has received numerous awards such as ASCO YIA and ASCO CDA, has over 280 publications (1200+ citations), listed in the top 1% scholar for citations by Clarivate in 2020, has reviewed 20+ journals and served as editorial board member of many top journals including Red Journal, Clinical Lung Cancer, and JCO. She is currently an associate editor for Journal of National Cancer Center (JNCC) and co-editor-in-Chief for Intelligent Oncology.
Xiaolin Zhu, MD, PhD
Dr. Zhu holds an MD from Shanghai Jiao Tong University School of Medicine and a PhD in Genetics and Genomics from Duke University. He completed his Internal Medicine Residency at UT Southwestern Medical Center and his Hematology/Oncology Fellowship at UCSF.
He specializes in prostate, bladder, and kidney cancers. His research focuses on studying biospecimens – for example, tumor and blood samples collected from patients – to understand how cancer evolves in response to treatments. His goal is to develop innovative diagnostic tools and treatment options to improve patients’ outcomes.